Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,